ReviewAging and disease2017
Recognizing Degenerative Aging as a Treatable Medical Condition: Methodology and Policy.
Review in Aging and disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Exercise delays aging: evidence from telomeres and telomerase -a systematic review and meta-analysis of randomized controlled trials.Frontiers in physiology · 2025Pooled it
- Cellular Senescence in Diabetic Cardiomyopathy: Mechanistic Insights and Therapeutic Perspectives.Cardiovascular drugs and therapy · 2026Review
- Intranasal Human NSC-Derived EVs Therapy Can Restrain Inflammatory Microglial Transcriptome, and NLRP3 and cGAS-STING Signalling, in Aged Hippocampus.Journal of extracellular vesicles · 2026Article
- Caloric restriction-mimetics for the reduction of heart failure risk in aging heart: with consideration of gender-related differences.Military Medical Research · 2022Review
- Promise of metformin for preventing age-related cognitive dysfunction.Neural regeneration research · 2022Review
- Recent Neurotherapeutic Strategies to Promote Healthy Brain Aging: Are we there yet?Aging and disease · 2022Review
- Editorial: Clinical Evaluation Criteria for Aging and Aging-Related Multimorbidity.Frontiers in genetics · 2021Article
- Anti-aging technoscience & the biologization of cumulative inequality: Affinities in the biopolitics of successful aging.Journal of aging studies · 2020Article
- Geroscience in the Age of COVID-19.Aging and disease · 2020Article
- The Use of Natural Agents to Counteract Telomere Shortening: Effects of a Multi-Component Extract ofBiomedicines · 2020Article
- Human ageing as a dynamic, emergent and malleable process: from disease-oriented to health-oriented approaches.Biogerontology · 2020Article
- Hydroxyurea Facilitates Manifestation of Disease Relevant Phenotypes in Patients-Derived IPSCs-Based Modeling of Late-Onset Parkinson's Disease.Aging and disease · 2019Article
- AMPK Signaling Regulates the Age-Related Decline of Hippocampal Neurogenesis.Aging and disease · 2019Article
- Health and Aging: Unifying Concepts, Scores, Biomarkers and Pathways.Aging and disease · 2019Review
- mTOR and Aging: An Old Fashioned Dress.International journal of molecular sciences · 2019Review
- Are We Ill Because We Age?Frontiers in physiology · 2019Review
- Ginger (Evidence-based complementary and alternative medicine : eCAM · 2019Review
- Emerging Anti-Aging Strategies - Scientific Basis and Efficacy.Aging and disease · 2018Review
- Disease or not, aging is easily treatable.Aging · 2018Article
- Genetically Engineered Resveratrol-Enriched Rice Inhibits Neuroinflammation in Lipopolysaccharide-Activated BV2 Microglia Via Downregulating Mitogen-Activated Protein Kinase-Nuclear Factor Kappa B Signaling Pathway.Oxidative medicine and cellular longevity · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is becoming increasingly clear that in order to accomplish healthy longevity for the population, there is an urgent need for the research and development of effective therapies against degenerative aging processes underlying major aging-related diseases, including heart disease, neurodegenerative diseases, type 2 diabetes, cancer, pulmonary obstructive diseases, as well as aging-related complications and susceptibilities of infectious communicable diseases. Yet, an important incentive for the research and development of such therapies appears to be the development of clinically applicable and scientifically grounded definitions and criteria for the multifactorial degenerative aging process (or "senility" using the existing ICD category), underlying those diseases, as well as for the safety and effectiveness of interventions against it. Such generally agreed definitions and criteria are currently absent. The devising of such criteria is important not only for the sake of their scientific value and their utility for the development of therapeutic solutions for the aging population, but also to comply with and implement major existing national and international programmatic and regulatory requirements. Some methodological suggestions and potential pitfalls for the development of such criteria are examined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.